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Abstract
This paper investigates the robustness of the shrinkage Bayesian estimator for the
relative potency parameter in the combinations of multivariate bioassays proposed
in Chen et al.(1999), which incorporated prior information on the model parame-
ters based on Jeffreys’ rules. This investigation is carried out for the families of
t-distribution and Cauchy-distribution based on the characteristics of bioassay the-
ory since the t-distribution approaches the normal distribution which is the most
commonly used distribution in the applications of bioassay as the degrees of freedom
increases and the t-distribution approaches the Cauchy-distribution as the degrees
of freedom approaches 1 which is also an important distribution in bioassay. A real
data is used to illustrate the application of this investigation. This analysis further
supports the application of the shrinkage Bayesian estimator to the theory of bioassay
along with the empirical Bayesian estimator.
Key Words: Bayesian analysis; Noninformative Prior; Posterior likelihood func-
tion; Posterior mode; Relative Potency.
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1 Introduction
Estimation of relative potency in biological assay (i.e. bioassay) is very important in phar-
maceutical and toxicological sciences. A variety of methods for estimating relative potency
can be found in the literature and the references in Finney (1978) and Govindarajulu
(2001). Most of these methods can be formulated in terms of a general linear model for
data following a normal distribution, or in a generalized linear model for other types of
data. In the situation of multi-response experiments, multivariate statistics can be used as
in Laska et al. (1985), Srivastava (1986) and Chen et al. (1999).
The combination of bioassays arises when the same or similar experiment is performed
by multi-laboratories and multi-centers in the calibration of national/international stan-
dards for a particular substance (Rose and Gaines-Das, 1998). With the studies of com-
bination of bioassays, most results appear in Bennett (1962), Armitage (1970), Meisner et
al. (1986), William (1988), Chen et al. (1999), Xiong and Chen (2007), and Chen (2007).
Chen et al. (1999) proposed a novel empirical Bayesian estimator (EBE) and a shrink-
age Bayesian estimator (SBE) for the relative potency from the combination of several
multivariate bioassays by incorporating prior information on the model parameters based
on Jeffreys’ rules. The EBE can account for any extra-variability among the bioassays,
and if the extra-variability is zero, the EBE reduces to the maximum likelihood estimator
for combinations of bioassays. The SBE estimator turned out to be a weighted average of
the prior information and the estimator from each bioassay with the weights depending on
the prior variance, which is not uncommon in Bayesian framework. The key advantage of
this shrinkage Bayesian estimator is that it can be written in closed form and therefore no
iterative process is involved to yield the estimate.
However any prudent Bayesian analysis should include an investigation of the robustness
of the posterior distribution to the specifications of commonly used prior distributions.
For the proposed shrinkage Bayesian estimator, Chen et al.(1999) embedded the Bayesian
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theory into a bioassay framework by using the Jeffreys’ theory for the model parameters.
This technique takes the advantage that some information is known about the log relative
potency parameter µ, while little information is known about the other parameters from
the model specification of the combination of multivariate bioassays. Therefore, the robust
investigation for the shrinkage Bayesian estimator is given to different specifications of the
prior distribution for the parameter of µ.
In this paper, the families of t- and Cauchy-distributions will be investigated for the
robustness analysis since practically t-distribution is considerably important, especially
for the heavy-tail distribution. As the degrees of freedom increases, the t-distribution ap-
proaches the normal distribution, which is the most commonly situation in the applications
of bioassay as illustrated in Finney (1978) and Chen et al. (1999). On the other hand, as
the degrees of freedom approaches 1, the t-distribution approaches the Cauchy distribution,
which is also an important distribution in bioassay since the log relative potency estimator
is a ratio of two normal variables, which is distributed as a Cauchy distribution.
This paper is organized as follows. Section 2 introduces the bioassay model and shrink-
age Bayesian estimator based on Jeffreys’ prior from Chen et al. (1999) and the investiga-
tion of two families of t-distribution and Cauchy-distribution is given in Section 3. A real
data analysis is illustrated in Section 4 with further discussions given in Section 5.
2 Combinations of Bioassays and Shrinkage Estimator
2.1 Model Specification
The experimental model for ith (i = 1, · · · , k) multivariate bioassay in the combinations of
k multivariate bioassays to estimate the relative potency of the test (t) preparation to the
standard (s) preparation is usually of the following form:
ysi = αsi + βsixsi + si
2
yti = αti + βtixti + ti (2.1)
where ysi ,yti ∈ Rp, p ≥ 1, are multivariate responses in the dose-response relationship,
αsi, αti, βsi, βti ∈ Rp are the multivariate parameters, and xsi, xti are the scalar inputs
as function of dose levels.
This model can then be casted in a multivariate regression framework
Yi = ΨiXi + i, (2.2)
where Yi = (ys1, . . . ,ysnsi ,yt1, . . . ,ytnti) is the p×ni matrix of responses with ni = nsi+nti,
where nsi, nti are the number of observations in the ith bioassay for the standard and test
preparations, respectively; and Ψi = (αi, δi,βi) is the p × 3 matrix of parameters. For
all i = 1, . . . , k, ′i s are assumed i.i.d. ∼ Np(0,V), where V is p × p positive definite
symmetric matrix.
Different assumptions on the model parameters can produce different bioassay models.
There are two commonly-known bioassays with one as parallel-line bioassay and another
as slope-ratio bioassay. In the parallel-line bioassays where the two slopes in equation (2.1)
on both test preparation (i.e. βti) and standard preparation (i.e. βsi) are equal (denoted
by βi) where βi = βsi = βti, (see for example, Carter and Hubert (1985) for the test of
the parallelism), but with different intercepts so that αi = αsi; δij = αtij−αij = µijβij, for
all bioassays i = 1, . . . , k, and all responses j = 1, . . . , p , where µij are scalar parameters,
which are the log relative potencies of the ith bioassay and jth response variable. The
slope-ratio bioassay has slightly different parameterizations where the slopes are different
but the intercepts are the same, such that αi = αsi = αti, δi = δti = µijβsi where µij
are the relative potencies in ith bioassay and jth response variable. We will illustrate
parallel-line bioassay in this paper and the similar discussions can be made for slope-ratio
bioassay.
In the situation of homogeneity, µij = µ for all i and j which can be tested by the
likelihood-ratio test. The p × ni random matrix i consists of ni columns of multivariate
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normal random vectors Np(0,V); and Xi is the 3 × ni design matrix defined as Xi =
1 · · · 1 1 · · · 1
0 · · · 0 1 · · · 1
xs1 · · · xsnsi xt1 · · · xtnti
 , where x’s are log dose levels. Then the multivariate
regression technique can be used to obtain the estimators
Ψˆi = YiX
′
i(XiX
′
i)
−1 (2.3)
Si = m
−1
i Yi
[
I−X′i ( XiX′i ) −1 Xi
]
Y′i (2.4)
as independent estimators of Ψi and V, where mi = ni−3 and X′ is the transpose of matrix
X. Since our interest is in the relative potency parameter µij, the second and third columns
of Ψˆi will be the relevant ones, while the parameters in the first column, αˆi, are the nuisance
parameters. Therefore, we will restrict our attention to
 δˆi
βˆi
 ∼ N2p
 δi
βi
 ,V ⊗Ai
 ,
where Ai is the lower 2× 2 portion of (XiX′i)−1.
To block diagonalize the matrix V ⊗Ai in order to make δˆi and βˆi independent, let’s
define Ti =
 t11i t12i
0 t22i
, such that TiAiT′i = I. Then, t11i = a1/222i(a11ia22i−a212i)1/2 , t12i =
−a12ia−1/222i
(a11ia22i−a212i)1/2
and t22i = a
−1/2
22i . Let ui = t11iδˆi+t12iβˆi and vi = t22iβˆi, then the distribution
of ui and vi is ui
vi
 ∼ N2p
 t11iδi + t12iβi
t22iβi
,V ⊗ I2
 . (2.5)
In addition, Si in equation (2.4) is distributed as Si ∼ m−1i Wp(V,mi) = Wp(V/mi,mi),
which is the Wishart distribution, a multivariate generalization of the Chi-square distribu-
tion, with the pdf given by Ci|V|−
mi
2 |Si|
mi−p−1
2 etr(−mi
2
V−1Si), where etr is the notation
for exponent of the trace, |V| is the determinant of matrix V and Ci is a constant of inte-
gration chosen so that the total probability is 1 (Srivastava and Carter, 1983). The pooled
estimator for V is then S = (
∑k
i=1miSi)/
∑k
i=1mi.
4
2.2 Shrinkage Bayesian Estimator for the Log Relative Potency
The shrinkage estimator was derived in Chen et al. (1999) based on Jeffreys’ prior (Hoadley,
1970) of pi(µ,βi,V) ∝ h(µ)|V|(p+1)/2 with h(µ) ∼ N(µ0, τ 2), for some µ0 and τ 2 > 0.
It was shown that µ|Xi, Yi,βi,V ∼ N(µp, τ 2p ) , where
µp =
τ 2
∑k
i=1 t11iβ
′
iV
−1(t11iδˆi + t12iβˆi − t12iβi) + µ0
τ 2
∑k
i=1 t
2
11iβ
′
iV
−1βi + 1
τp =
(
k∑
i=1
t211iβ
′
iV
−1βi +
1
τ 2
)− 1
2
.
Then the shrinkage Bayesian estimator(SBE) for the log relative potency, µ, can be
obtained using the estimates in equations (2.3) and (2.4) for βi and V as follows:
µSBE =
τ 2
∑k
i=1 t
2
11iβˆi
′
S−1i δˆi + µ0
τ 2
∑k
i=1 t
2
11iβˆi
′
S−1i βˆi + 1
(2.6)
τSBE =
(
k∑
i=1
t211iβˆi
′
S−1i βˆi +
1
τ 2
)− 1
2
. (2.7)
Therefore the credible region with (1-α)100% coefficient for µ can be expressed as µSBE ±
zα/2 τSBE where zα/2 is the usual percentile point such that 1 - Φ(zα/2) = α/2, and where
Φ(·) is the cumulative distribution function for a standard normal random variable.
The corresponding noninformative shrinkage Bayesian estimator can be obtained by
letting τ approaches infinite as follows:
ˆˆµ =
∑k
i=1 t
2
11iβˆi
′
S−1i δˆi∑k
i=1 t
2
11iβˆi
′
S−1i βˆi
(2.8)
ˆˆτ =
(
k∑
i=1
t211iβˆi
′
S−1i βˆi
)− 1
2
. (2.9)
Similar (1-α)100% credible region for µ can be expressed as ˆˆµ± zα/2 ˆˆτ .
The advantage for this shrinkage Bayesian estimator and its interval estimator described
above is that they can be calculated explicitly from the model parameter estimates which
have been obtained from equations (2.3) and (2.4). No iterative process is involved.
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3 Robust Analysis for the Shrinkage Bayesian Esti-
mator
Since, in most practical situations, some information can be known about the relative
potency, µ and relatively little information is known about βi and V, then by Jeffreys’
rules, a suitable prior distribution would be pi(µ,βi,V) ∝ h(µ)|V|(p+1)/2 , where h(µ) is a proper
prior distribution for µ. Then the posterior distribution of µ, conditional on X i , Y i , βi
and V can be shown from equation (2.5) as follows:
µ|X i,Y i,βi,V ∝ pi(µ,βi,V) L(µ,βi,V)
∝ h(µ)exp
{
−1
2
k∑
i=1
(t11iδˆi + t12iβˆi − t11iµβi − t12iβi)′V−1(t11iδˆi + t12iβˆi − t11iµβi − t12iβi)
}
.
(3.1)
The posterior function (3.1) incorporates all the information from the data by the
likelihood function and prior information from h(µ). Parallel to the maximum likelihood
theory, an estimate of the log relative potency can be obtained by maximizing the posterior
likelihood function, i.e. estimating the log relative potency parameter by the mode of the
posterior likelihood function. Another alternative is to estimate the log relative potency
parameter by the median or mean of the posterior likelihood function. This estimator
is usually referred as the posterior Bayesian estimator (Mood et al. 1973). However if
the prior distribution is normal, these two alternatives produce same estimators, since
the posterior distribution is also normally distributed. Actually, if h(µ) is the normal
distribution N(µ0, τ
2) and after simple manipulations, the same results in Section 2.2 can
be derived.
For the posterior Bayesian estimator, numerical integration is involved to obtain this
estimator. Therefore, to be concise for this robustness analysis and also parallel to the con-
ventional likelihood estimation, the mode of the posterior likelihood function (3.1) is used
in this paper for the robustness analysis to different specifications of the prior distribution.
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This estimator is then referred to as the shrinkage estimator (SBE). The same analysis can
be carried out for posterior Bayesian estimator.
3.1 Robustness of Shrinkage Estimator under t-Prior Density
If µ is distributed as a t-distribution with n(n > 0) degrees of freedom, location parameter
µ0 and scale parameter τ , then the density function is:
h(µ) =
Γ(n+1
2
)
Γ(n
2
)
1√
npi
1
τ
1[
1 + 1
n
(µ−µ0
τ
)2
]n+1
2
, −∞ < µ <∞, (3.2)
where E(µ) = µ0 and V ar(µ) =
n
n−2 τ
2 ( −∞ < µ0 <∞ , τ > 0). It can be shown that the
larger n value or the smaller τ value, the more peaked for the distribution and as n→∞,
V ar(µ) → τ 2, which is the smallest value for V ar(µ). Theoretically, for sufficient larger
value of n, the t-distribution is back to normal distribution.
The shrinkage estimator can be obtained by taking the derivative of (3.1) with respect
to µ and letting it to be zero. The following equation is obtained:
2aµ3+(−b−4aµ0)µ2+(−1−n+2bµ0+2anτ 2+2aµ20)µ−bnτ 2+nµ0+µ0−bµ20 = 0 . (3.3)
It can be shown that there is only one real root for this equation which is
µ(n;µ0, τ) =
1
6
J(n;µ0, τ)
2
3 − 6ag2 + g21 − g1J(n;µ0, τ)
1
3
aJ(n;µ0, τ)
1
3
, (3.4)
where:
J(n;µ0, τ) = 9ag1g2 − 54a2g3 − g31 + 3
√
3 a (8ag32 − g21g22 − 36ag1g2g3 + 108a2g23 + 4g31g3)
1
2
g1 = −b− 4aµ0
g2 = −1− n+ 2bµ0 + 2anτ 2 + 2aµ20
g3 = −bnτ 2 + nµ0 + µ0 − bµ20
a = −1
2
k∑
i=1
t211iβi
′V−1βi
b = −
k∑
i=1
t11iβi
′V−1(t11iδˆi + t12iβˆi − t12iβi) .
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Since the parameters βi and V are unknown, the true value of this shrinkage estimator
is unknown. However, independent estimates of βi and V are available from (2.3) and
(2.4). Thus, an empirical shrinkage estimator can be formed by replacing the estimators
from (2.3) and (2.4) into (3.4) as follows:
µˆ(n;µ0, τ) =
1
6
Jˆ(n;µ0, τ)
2
3 − 6aˆgˆ2 + gˆ21 − gˆ1Jˆ(n;µ0, τ)
1
3
aˆJˆ(n;µ0, τ)
1
3
, (3.5)
It can be easily proven from (3.5) that
µˆ(n;µ0, τ)→ bˆτ
2 − µ0
2aˆτ 2 − 1 =
bˆ− µ0/τ 2
2aˆ− 1/τ 2 as n→∞. (3.6)
which is the shrinkage Bayesian estimator (µSBE) obtained in equation (2.6). Therefore
µˆ(n;µ0, τ) → bˆ2aˆ = ˆˆµ (i.e. the estimator in equation (2.8)) as n → ∞ and τ → ∞ which
is insensitive to the different specifications of the prior density and is just a function of
the data. That is to say, in this situation, this empirical shrinkage estimator from t-family
is very robust to various specifications of the prior parameters. In fact, as n → ∞, the
t-distribution is back to normal distribution and also, as τ → ∞, the empirical shrink-
age estimator µˆ(n;µ0, τ) approaches the noninformative shrinkage Bayesian estimator, ˆˆµ,
proposed in Chen et al. (1999), which is
ˆˆµ =
∑k
i=1 t
2
11iβˆi
′
S−1i δˆi∑k
i=1 t
2
11iβˆi
′
S−1i βˆi
. (3.7)
This estimator ˆˆµ represents a noninformative or uniform prior and can be rewritten as
ˆˆµ =
∑k
i=1
t211i
ˆβi
′
S−1i
ˆβi∑k
i=1
t211i
ˆβi
′
S−1i
ˆβi
µˆi, which is the weighted average of estimators of log relative
potency from ith bioassay, µˆi, with the weights depending only on the maximum likelihood
estimates of the model parameters. Therefore, in the situation of no prior information, this
estimator (ˆˆµ) is recommended.
The above outcomes strongly suggests that in the t-distribution and normal distri-
bution, the shrinkage Bayesian estimator proposed in Chen et al. (1999) is robust for
different specifications of prior distributions and approaches the noninformative shrinkage
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Bayesian estimator. However, the noninformative shrinkage Bayesian estimator ˆˆµ is prior-
independent and possesses the advantages that ˆˆµ is the weighted average of estimators of
log relative potency from each bioassay with the weights depending only on the maximum
likelihood estimates of the model parameters. It can be used to estimate the log relative
potency in the bioassay theory.
3.2 Robustness of Shrinkage Estimator under Cauchy Distribu-
tion
Not only is the Cauchy prior distribution the extreme situation in the Section 3.1 when
n = 1, but also it is special in the theory of bioassay. The well-known fact in bioassay
theory is that the estimated log relative potency is the ratio of two normal variables. But
the ratio of two normal variables is distributed as a Cauchy distribution. From this point
of view, the Cauchy distribution is relatively more important. In this section, the Cauchy
distribution is considered as the prior for the robustness analysis.
If µ is distributed by a Cauchy distribution, then the density function is h(µ) =
1
piτ{1+(µ−µ0τ )2} , where τ > 0 is the scale parameter and µ0 (−∞ < µ0 < ∞) is the lo-
cation parameter. The same procedures as in Section 3.1 yields the shrinkage estimator:
µ(µ0, τ) = −1
6
−J
2
3
µ0,τ − 12a+ 12a2τ 2 − 4a2µ20 + 4abµ0 − b2 − 4aµ0J
1
3
µ0,τ − bJ
1
3
µ0,τ
aJ
1
3
µ0,τ
, (3.8)
where:
Jµ0,τ = −[36a2µ0 − 18ab+ 72a3τ 2µ0 − 36a2bτ 2 + 8a3µ30 − 12a2bµ20 + 6ab2µ0 − b3
−6
√
3a(−16a+ 4abµ0 + 80a3τ 2µ20 + 20aτ 2b2 + 32a4τ 4µ20 + 8a2b2τ 4
+16a4τ 2µ40 + τ
2b4 + 48a2τ 2 − 4a2µ20 − b2 − 48a3τ 4 + 16a4τ 6 − 80a2bτ 2µ0
−32a3τ 2bµ30 + 24a2τ 2µ20b2 − 8aτ 2b3µ0 − 32a3τ 4bµ0)
1
2 ]
a = −1
2
k∑
i=1
t211iβi
′V−1βi
b = −
k∑
i=1
t11iβi
′V−1(t11iδˆi + t12iβˆi − t12iβi) .
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Then the empirical shrinkage estimator can be obtained by replacing the estimators
from (2.3) and (2.4). This results in:
µˆ(µ0, τ) = −1
6
−Jˆ
2
3
µ0,τ − 12aˆ+ 12aˆ2τ 2 − 4aˆ2µ20 + 4aˆbˆµ0 − bˆ2 − 4aˆµ0Jˆ
1
3
µ0,τ − bˆJˆ
1
3
µ0,τ
aˆJˆ
1
3
µ0,τ
, (3.9)
Similarly, it can be proven that
µˆ(µ0, τ)→ ˆˆµ as τ →∞. (3.10)
In this case the empirical shrinkage estimator again approaches the noninformative shrink-
age Bayesian estimator proposed in Chen et al. (1999).
3.3 The Ideal Shrinkage Estimator
The results from both Sections 3.1 and 3.2 imply that as µ0 → ˆˆµ, the empirical shrinkage
estimator µˆ(n;µ0, τ) in (3.5) and µˆ(µ0, τ) in (3.9) will both be robust irrespective of the
prior variance τ 2. That is to say, if the data contain sufficient information to make the
prior distribution concentrate on the prior means, or the prior distribution is chosen to
match the data “perfectly”, then the empirical shrinkage estimator is very robust to differ-
ent specifications of prior. Otherwise, if the prior disagrees sharply with the information
contained in the data, the empirical shrinkage estimator is less robust.
Therefore, to estimate the log relative potency in combination of bioassays, the plausible
procedure is to use the estimators from (2.3) and (2.4) to estimate a prior mean and
prior standard deviation on any k − 1 of k bioassays. Next utilize them as the prior
information to form the final shrinkage estimator for the last bioassay, which is robust
and has all the properties previously described. Hence, it is named as the ideal shrinkage
estimator. This ideal shrinkage estimator is superior to the general shrinkage estimator
and the noninformative shrinkage estimator because the prior distribution is formulated
from the data, yielding a more accurate estimator.
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4 Data Analysis
Data was originally from Finney (1978). In illustrating the combination of multivariate
bioassays, Meisner, Kushner and Laska (1986) artificially broke up the data into two mul-
tivariate bioassays with the first bioassay using the twelve bivariate responses from lines 1
and 3 and the second bioassay using the twelve bivariate responses from lines 2 and 4. The
summary statistics are given in Table 1 for the two assays.
Table 1: Summary Statistics of the Two Assays
Assay i βˆi δˆi
 t11i t12i
0 t22i
 miSi
1
 16.625
−3.125
  −8.5
2.3333
 
√
3 0
0
√
8
  1475.0417 126.625
126.625 68.5417

2
 27.125
−2.5
 −15.8333
1.16667
 
√
3 0
0
√
8
  6042.7083 218.5
218.5 80.8333

As seen in Chen et al (1999), the test for equality of covariance can not be rejected
since the test statistic is 4.107, which is less than χ23,0.05=7.815. Consequently we can use
the pooled variance-covariance as follows:
S =
 417.653 19.174
9.174 8.299
 .
Based on these values, the noninformative shrinkage estimate for the overall log relative
potency ˆˆµ in equation (2.8) can be calculated to be -0.590 with 95% CI as (-1.039, -0.141),
suggesting the test preparation is significantly less potent than the standard preparation
in this combination of bioassays.
To graphically illustrate the robustness analysis in Section 3, Figure 1 displays this
empirical shrinkage estimator µˆ(n; 0, τ) in equation (3.5) versus n and τ for fixed µ0 = 0
based on this data. It can be seen from Figure 1 that even though the shrinkage estimator
µˆ(n;µ0, τ) differs for different specifications of values of n, µ0 and τ , but as n and τ are
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sufficiently large enough, the empirical shrinkage estimator µˆ(n;µ0, τ) quickly approaches
the noninformative empirical Bayesian estimator ˆˆµ in equation (2.8) and appears to be
robust irrespective of the specifications of n, µ0 and τ in t-distribution family.
n
2
4
6
8
10
tau
0.0
0.2
0.4
0.6
0.8
1.0
hatm
u
−0.5
−0.4
−0.3
−0.2
−0.1
0.0
Figure 1: µˆ(n ; 0 , τ ) as the function of n and τ with the prior of t-distribution.
Similar conclusion can be made for the empirical shrinkage estimator µˆ(µ0, τ) in equa-
tion (3.9) versus µ0 and τ as shown in Figure 2. It can be seen from Figure 2 that if
τ is sufficiently large, µˆ(µ0, τ) quickly approaches the noninformative empirical Bayesian
estimator ˆˆµ in equation (2.8) and appears to be robust irrespective of the value at µ0. If
the prior mean µ0 → ˆˆµ, µˆ(µ0, τ) is robust regardless of the values for τ .
12
m
u0
−0.4
−0.2
0.0
0.2
0.4
tau
0.2
0.4
0.6
0.8
1.0
m
uhat
−0.5
−0.4
−0.3
−0.2
−0.1
0.0
Figure 2: µˆ(µ0, τ) as the function of µ0, τ with the prior of Cauchy distribution.
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To numerically illustrate the robustness, Table 2 gives the values of the empirical shrink-
age estimator µˆ(n, µ0, τ) in equation (3.5) for several specifications of n, µ0 and τ . In the
table, four values of n = 1, 5, 10, 50 are illustrated which are column-headed by µˆ(1, µ0, τ),
µˆ(5, µ0, τ), µˆ(10, µ0, τ) and µˆ(50, µ0, τ). The first column µˆ(1, µ0, τ) is in fact µˆ(µ0, τ) in
equation (3.9) since whenever n = 1, the t-distribution becomes the special case of Cauchy
distribution and therefore µˆ(n, µ0, τ) in equation (3.5) would be µˆ(µ0, τ) in equation (3.9).
The last column µˆ(50, µ0, τ) illustrates the empirical shrinkage estimator with large degrees
of freedom from t-distribution which would be very similar to the normal prior. Therefore
this last column would mimic the shrinkage Bayesian estimator µSBE in equation (2.6)
as proposed in Chen et al (1999). The middle two columns illustrate the t-distribution
between Cauchy and normal distributions.
In Table 2, three values of µ0 are chosen where µ0 = −0.5 is close to the noninformative
empirical estimator ˆˆµ = −0.590 and other two values of 0 and 0.5 are chosen farther
away from ˆˆµ. Five values of τ are chosen from 0.1 (small), 0.5, 1, 2 to 3 (large). It can be
clearly seen from Table 2 that all µˆ(1, µ0, τ), µˆ(5, µ0, τ), µˆ(10, µ0, τ) and µˆ(50, µ0, τ) rapidly
approach the ˆˆµ = −0.590 irrespective of the different specifications of µ0 and τ . This is
especially true with µ0 = −0.5 which again indicates that when an appropriate prior is
selected, the three shrinkage estimators of µSBE in equation (2.6), µˆ(n, µ0, τ) in equation
(3.5) and µˆ(µ0, τ) in equation (3.9) could all approximate the noninformative shrinkage
Bayesian estimator ˆˆµ in equation (2.8).
This leads to the ideal shrinkage estimator proposed in Section 3.3 to use any k − 1 of
the k bioassays as the prior information to compute a prior mean µˆ0 using equation (2.8)
and prior standard deviation τˆ0 using equation (2.9) and then utilize these values to form
the final shrinkage estimator using equations (2.6) and (2.7) with the kth bioassay. This
can be easily implemented for this data. We take the first bioassay to compute a prior
mean µˆ0 using equation (2.8) and prior standard deviation τˆ0 using equation (2.9) which
are µˆ0 = −0.654 and τˆ0 = 0.351. We can then use these values as in the normal prior to
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Table 2: Numerical illustration of the empirical Bayesian estimator µˆ(n, µ0, τ) for different
specifications of n = 1, 5, 10, 50, µ0 = −0.5, 0, 0.5 and τ = 0.1, 0.5, 1.0, 2.0, 3.0. The
bolded values indicate µˆ(n, µ0, τ) approaches the noninformative shrinkage estimator ˆˆµ =
−0.590.
µ0 τ µˆ(1, µ0, τ) µˆ(5, µ0, τ) µˆ(10, µ0, τ) µˆ(50, µ0, τ)
-0.5 0.1 -0.508 -0.512 -0.513 -0.514
-0.5 0.5 -0.564 -0.572 -0.573 -0.574
-0.5 1.0 -0.582 -0.585 -0.585 -0.586
-0.5 2.0 -0.588 -0.589 -0.589 -0.589
-0.5 3.0 -0.589 -0.590 -0.590 -0.590
0.0 0.1 -0.079 -0.093 -0.094 -0.094
0.0 0.5 -0.485 -0.487 -0.488 -0.488
0.0 1.0 -0.546 -0.557 -0.559 -0.561
0.0 2.0 -0.576 -0.581 -0.582 -0.583
0.0 3.0 -0.584 -0.586 -0.587 -0.587
0.5 0.1 -0.485 -0.165 0.274 0.319
0.5 0.5 -0.507 -0.451 -0.431 -0.408
0.5 1.0 -0.538 -0.537 -0.536 -0.536
0.5 2.0 -0.569 -0.574 -0.575 -0.576
0.5 3.0 -0.579 -0.583 -0.584 -0.584
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calculate a final estimate using equations (2.6) and (2.7) from the second bioassay. In this
situation, these two equations are actually reduced to:
µIdeal =
τˆ 20 t
2
112βˆ2
′
S−1δˆ2 + µˆ0
τˆ 20 t
2
112βˆ2
′
S−1βˆ + 1
(4.11)
τIdeal =
(
t2112βˆ2
′
S−1βˆ2 +
1
τˆ 20
)− 1
2
. (4.12)
And they are estimated as µIdeal = −0.590 and τIdeal = 0.229 with associated 95% CI as
(-1.039,-0.141). Similarly if we take the second bioassay to compute the prior mean µˆ0 and
prior standard deviation τˆ0, we can get µˆ0 = −0.543 and τˆ0 = 0.302. Using these values
in the normal prior to calculate the final estimate using equations (4.11) and (4.12) on the
first bioassay, we can obtain µIdeal = −0.590 and τIdeal = 0.229 with associated 95% CI as
(-1.039,-0.141) which yields the exact numeric values.
All the calculations in this section are done in R (a free software available from http://www.r-
project.org) and the R program can be requested from the author.
5 Discussion
In this paper the investigation of the robustness of the shrinkage Bayesian estimator was
conducted for two commonly-known families of t-distribution and Cauchy-distribution. It
was shown that the shrinkage estimator would change for different specifications of differ-
ent prior distributions. But if the prior variance is large enough or the prior information
matches the “data”, the shrinkage estimator is robust and approaches the noninformative
shrinkage Bayesian estimator which is insensitive to different specifications of prior distri-
bution and is only data-dependent. A real data analysis demonstrated these conclusions.
As seen from the data analysis, the three shrinkage estimators from the normal distribu-
tion (in Chen et al. 1999), the t-distribution and the Cauchy-distribution approached to
the noninformative shrinkage Bayesian estimate of ˆˆµ = −0.590 within wide range of prior
variance τ 2.
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If the prior information is indeed available, the shrinkage Bayesian estimator proposed
in Chen et al. (1999) can be readily applied to the prior information directly and hence
a Bayesian estimator can be calculated using the procedures in this paper. Otherwise,
the ideal shrinkage estimator proposed in Section 3.3 could be adopted for the estimation
of the relative potency for combination of bioassays. This ideal shrinkage estimator was
demonstrated to be valid and applicable which also produced the same results as the
noninformative shrinkage Bayesian estimator from the real data analysis.
In fact, the procedure in this paper is very general and can be used for any specification
of the prior density. Not only can it be used for robust analysis, it can also be used to
propose different Bayesian estimators under different prior specifications. As a summary, it
can be concluded that the Bayesian approach is a recommended in the theory of bioassay.
Furthermore, this newly-developed Bayesian procedure is applicable for the combination
of univariate bioassays (Xiong and Chen 2007), combination of multivariate bioassays,
parabolic bioassays (Chen 2010), as well as combination of parabolic bioassays. It has
been shown that it is superior to some conventional methods. The robust investigation in
this paper makes a good conclusion for its properties and provides a strong recommendation
for its use. Hence, the Bayesian method is a natural way to improve the theory of bioassay.
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